# Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)

> **NCT00413023** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 348 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** GW679769

## Key facts

- **NCT ID:** NCT00413023
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 348 (ACTUAL)
- **Last updated:** 2016-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00413023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00413023, "Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00413023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*